Solventum Corporation (SOLV) SEC Filings & Earnings Calls
EquiReason read 15 Solventum Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-08-05 — Solventum announces intent to separate Health Information Systems business, a portfolio optimization event that unlocks shareholder value and sharpens MedTech focus..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 14.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
5 Aug 20268-K · 7.01, 8.01Solventum announces intent to separate Health Information Systems business, a portfolio optimization event that unlocks shareholder value and sharpens MedTech focus.open
Figures in the filing · each found in the filing text
| clinical documents processed monthly · Health Information Systems · point_in_time | 660,000,000 | |
| addressable market size · Health Information Systems · point_in_time | $10.00B |
Risks flagged
Execution risk in separation process and potential disruption to ongoing operations.
“Separation pathways under evaluation; no definitive timeline or structure announced.”
5 Aug 20268-K · 2.02Solventum reported Q2 2026 sales of $2.2B (+9.5% organic), adjusted EPS $2.55 (+50.9%), raised FY2026 guidance for organic sales, adjusted EPS, and free cash flow, and announced intent to separate Health Information Systems segment.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $2.21B | +2% y/y |
| Organic sales growth · Q2-2026 | 9.5% | |
| Adjusted diluted earnings per share · Q2-2026 | $2.55 | +51% y/y |
| GAAP diluted earnings per share · Q2-2026 | $0.53 | +4% y/y |
| Operating cash flow · Q2-2026 | $227M | +34% y/y |
| Free cash flow · Q2-2026 | $144M | +144% y/y |
| Adjusted operating income margin · Q2-2026 | 28.4% | |
| Advanced Wound Care net sales · Advanced Wound Care · Q2-2026 | $537M | +15% y/y |
| Infection Prevention and Surgical Solutions net sales · Infection Prevention and Surgical Solutions · Q2-2026 | $836M | +11% y/y |
| Dental Solutions net sales · Dental Solutions · Q2-2026 | $396M | +17% y/y |
Guidance
FY2026 organic sales growth raised to +2.5% to +3.0% from +2.0% to +3.0%; adjusted EPS raised to $7.10-$7.20 from upper end of $6.40-$6.60; free cash flow raised to $200M-$300M
Solventum raised full-year 2026 guidance for organic sales growth, adjusted EPS, and free cash flow, reflecting strong execution and confidence in continued performance.
Risks flagged
Separation of Health Information Systems segment introduces execution risk and potential distraction.
“Announced the intent to separate its Health Information Systems business segment.” · word for word
GAAP operating margin declined 170 bps due to separation and restructuring costs.
“GAAP operating income margin decreased, primarily driven by net legal costs, separation and restructuring costs.” · word for word
5 Aug 202610-QSolventum reported strong Q2 2026 results with 9.5% organic sales growth and significant margin expansion across all segments, though total operating income declined due to corporate costs.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $2.21B | +2% y/y |
| Organic sales growth · Q2-2026 | 9.5% | |
| Segment operating income - MedSurg · MedSurg · Q2-2026 | $355M | +69% y/y |
| Segment operating income - Dental Solutions · Dental Solutions · Q2-2026 | $131M | +36% y/y |
| Segment operating income - Health Information Systems · Health Information Systems · Q2-2026 | $145M | +21% y/y |
| Operating income · Q2-2026 | $181M | -16% y/y |
| Interest expense, net · Q2-2026 | $64M | -38% y/y |
| Cash and cash equivalents · 2026-06-30 | $403M | |
| Share repurchases · Q2-2026 | $288M |
Guidance
Q3 2026 sales expected to be negatively impacted by ~$125M due to ERP deployment demand pull-forward reversal
Strong underlying demand but Q3 faces a headwind from advanced ordering reversal; margin trends positive.
Risks flagged
ERP deployment demand pull-forward reversal
“The Company anticipates that sales in the third quarter of 2026 will be negatively impacted as customers reduce inventory to normal levels.” · word for word
Tariff cost pressure
“Higher product costs due to tariffs and other inflation, including freight.” · word for word
Corporate cost overhang
“Corporate and Unallocated increased to $(469) million for the three months ended June 30, 2026 from $(263) million for the same period in 2025.”
5 Jun 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen
Risks flagged
Settlement of stockholder litigation over bylaw provisions; $120k payment.
“The Company subsequently decided to avoid further litigation ... agreeing to pay $120,000 in attorneys' fees and expenses.”
5 May 20268-K · 2.02Net Sales $2.01B (-3% y/y); Organic Sales Growth 2.1; Adjusted Diluted EPS $1.48 (+11% y/y); Guidance: Organic sales growth +2-3%; adjusted EPS toward high end of $6.40-6.60; FCF ~$200M.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q1-2026 | $2.01B | -3% y/y |
| Organic Sales Growth · Q1-2026 | 2.1% | |
| Adjusted Diluted EPS · Q1-2026 | $1.48 | +11% y/y |
| GAAP Diluted EPS · Q1-2026 | $0.07 | -91% y/y |
| Operating Cash Flow · Q1-2026 | $-189M | |
| Free Cash Flow · Q1-2026 | $-273M | |
| Adjusted Operating Income Margin · Q1-2026 | 19.5% |
Guidance
Organic sales growth +2-3%; adjusted EPS toward high end of $6.40-6.60; FCF ~$200M.
Affirmed FY2026 guidance; adjusted EPS expected toward high end of range.
Risks flagged
Negative free cash flow due to separation activities and transition payments.
“Operating cash flow $(189)M; free cash flow $(273)M driven by separation activities, transition agreement exit payments and normal seasonality.”
Tariff and inflation headwinds pressuring margins.
“Partially offset by tariffs and inflation headwinds; tariffs and inflation partially offset operational improvements.” · word for word
5 May 202610-QTotal Revenue $2.01B (-3% y/y); Organic Sales Growth 2.1; Operating Income $81M (-47% y/y)open
Figures in the filing · each found in the filing text
| Total Revenue · Q1-2026 | $2.01B | -3% y/y |
| Organic Sales Growth · Q1-2026 | 2.1% | |
| Operating Income · Q1-2026 | $81M | -47% y/y |
| MedSurg Revenue · MedSurg · Q1-2026 | $1.23B | +7% y/y |
| Dental Solutions Revenue · Dental Solutions · Q1-2026 | $354M | +8% y/y |
| Health Information Systems Revenue · Health Information Systems · Q1-2026 | $342M | +4% y/y |
| MedSurg Operating Income · MedSurg · Q1-2026 | $161M | -22% y/y |
| Dental Solutions Operating Income · Dental Solutions · Q1-2026 | $87M | +11% y/y |
| Health Information Systems Operating Income · Health Information Systems · Q1-2026 | $130M | +20% y/y |
| Cash and Cash Equivalents · Q1-2026 | $561M |
Risks flagged
Tariff Impact on Margins
“The increase was driven by increased costs due to the impact of higher sourcing costs, including tariffs which did not impact the first quarter of 2025.” · word for word
Separation Costs
“The increase was driven by higher costs associated with activities to separate operations from 3M and the cost of actions, net of savings from our Transform for the Future restructuring program.” · word for word
International Sales Decline
“In the International geographic area, both total sales and organic sales decreased.” · word for word
27 Mar 2026DEF 14AProxy statement for 2026 annual meeting, detailing executive compensation, governance, and 2025 performance.open
Figures in the filing · each found in the filing text
| Net Sales · FY2025 | $8.32B | +1% y/y |
| Organic Sales Growth · FY2025 | 3.3% | |
| Diluted GAAP EPS · FY2025 | $8.88 | |
| Adjusted Diluted EPS · FY2025 | $6.11 | |
| Operating Cash Flow · FY2025 | $369M | |
| Free Cash Flow · FY2025 | $-10M | |
| Adjusted Free Cash Flow (for compensation) · FY2025 | $530M | |
| Adjusted Operating Income · FY2025 | $1.77B | |
| Constant Currency Revenue · FY2025 | $8.38B | |
| MedSurg Organic Sales Growth · MedSurg · FY2025 | 3.5% |
Guidance
Organic sales growth nearly tripled year-over-year; adjusted operating income exceeded target (131% payout); free cash flow exceeded target (120% payout)
Management expresses confidence in achieving long-range plan targets faster than anticipated, with strong 2025 performance across revenue, margins, and cash flow.
Risks flagged
Dependence on 3M for supply and transition services
“3M is the sole source of supply for raw materials used in certain of our products and our business will be harmed if 3M does not satisfy our requirements.” · word for word
Execution risk of restructuring and transformation
“Solventum's restructuring program may not be successful.” · word for word
Cybersecurity and data breach risk
“Security and data breaches, cyberattacks and other cybersecurity incidents involving Solventum’s information technology systems and infrastructure could disrupt or interfere with Solventum’s operations.” · word for word
27 Feb 202610-KTotal Sales by Segment (MedSurg) 57.9; Total Sales by Segment (Dental Solutions) 16.2; Total Sales by Segment (Health Information Systems) 16.3open
Figures in the filing · each found in the filing text
| Total Sales by Segment (MedSurg) · MedSurg · FY2025 | 57.9% | |
| Total Sales by Segment (Dental Solutions) · Dental Solutions · FY2025 | 16.2% | |
| Total Sales by Segment (Health Information Systems) · Health Information Systems · FY2025 | 16.3% | |
| Outstanding Indebtedness · 2025-12-31 | $5.00B | |
| Number of Employees · 2025-12-31 | 20,000 | |
| 3M Ownership Stake · 2025-12-31 | 14.8% |
Risks flagged
Spin-off execution risk
“Solventum may not achieve some or all of the expected benefits of the Spin-Off.” · word for word
High leverage
“as of December 31, 2025, Solventum had approximately $5 billion of outstanding indebtedness.” · word for word
PFAS liability
“Solventum may face potential liabilities related to PFAS, which could adversely impact Solventum’s results.” · word for word
Single-source supplier (3M)
“3M is the sole source of supply for raw materials used in certain of our products and our business will be harmed if 3M does not satisfy our requirements.” · word for word
26 Feb 20268-K · 2.02Net sales $2.00B (-4% y/y); Net sales $8.32B (+1% y/y); Adjusted diluted EPS $1.57 (+11% y/y); Guidance: FY2026 organic sales growth +2-3%, adjusted EPS $6.40-$6.60, FCF ~$200Mearningsopen
Figures in the filing · each found in the filing text
| Net sales · Total · Q4-2025 | $2.00B | -4% y/y |
| Net sales · Total · FY2025 | $8.32B | +1% y/y |
| Adjusted diluted EPS · Q4-2025 | $1.57 | +11% y/y |
| Adjusted diluted EPS · FY2025 | $6.11 | -9% y/y |
| Free cash flow · Q4-2025 | $33M | -64% y/y |
| Free cash flow · FY2025 | $-10M | -101% y/y |
| Organic sales growth · Total · Q4-2025 | 3.5% |
Guidance
FY2026 organic sales growth +2-3%, adjusted EPS $6.40-$6.60, FCF ~$200M
FY2026 guidance implies organic sales growth acceleration and adjusted EPS growth of 5-8% vs FY2025.
Risks flagged
Free cash flow negative for FY2025; tariff headwinds impacting margins.
“Free cash flow of $(10) million for full year 2025; incremental tariff headwinds noted.”
16 Dec 20258-K · 7.01Guidance: raised 2025 outlook multiple timesopen
Guidance
raised 2025 outlook multiple times
Multiple guidance raises in 2025, margin progress, and strong volume growth.
6 Nov 202510-QSolventum completed sale of Purification and Filtration business for ~$4 billion, resulting in $1.5 billion gain and strengthened balance sheet.being acquiredopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $2.10B | +1% y/y |
| Organic growth · Q3-2025 | 2.7% | |
| Operating income · Q3-2025 | $1.69B | +515% y/y |
| Gain on sale of business · Q3-2025 | $1.50B | |
| Cash and cash equivalents · Q3-2025 | $1.64B | |
| MedSurg net sales · MedSurg · Q3-2025 | $1.21B | +2% y/y |
| Dental Solutions net sales · Dental Solutions · Q3-2025 | $340M | +8% y/y |
| Health Information Systems net sales · Health Information Systems · Q3-2025 | $345M | +6% y/y |
| Cost of product as % of sales · Q3-2025 | 53.1% | |
| SG&A as % of total net sales · Q3-2025 | 37.2% |
Risks flagged
Tariff cost pressure
“The increase was driven by increased costs due to the impact of higher sourcing costs from tariffs and inventory sourced under the master supply and transition manufacturing agreements with 3M, partially offset by benefits from cost savings programs.” · word for word
Separation and transition costs
“The increase was driven by higher costs associated with activities to separate operations from 3M, costs incurred to separate the Purification and Filtration business, and higher compensation expense, including equity-based awards, partially offset by benefits from the Solventum Way restructuring program.” · word for word
6 Nov 20258-K · 2.02Net Sales $2.10B (+1% y/y); Organic Sales Growth 2.7; GAAP Diluted EPS $7.22 (+931% y/y); Guidance: Full-year adjusted EPS raised to $5.98-$6.08 from $5.88-$6.03; organic sales growth raised to high end of 2-3%earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q3-2025 | $2.10B | +1% y/y |
| Organic Sales Growth · Q3-2025 | 2.7% | |
| GAAP Diluted EPS · Q3-2025 | $7.22 | +931% y/y |
| Adjusted Diluted EPS · Q3-2025 | $1.50 | -9% y/y |
| Operating Cash Flow · Q3-2025 | $75M | -56% y/y |
| Free Cash Flow · Q3-2025 | $-22M | -129% y/y |
| Adjusted Operating Income Margin · Q3-2025 | 20.6% | |
| Annual Cost Savings Target · FY2025 | $500M |
Guidance
Full-year adjusted EPS raised to $5.98-$6.08 from $5.88-$6.03; organic sales growth raised to high end of 2-3%
Raised full-year guidance on organic sales and adjusted EPS; margin pressure from tariffs and investments; new cost savings program announced.
Risks flagged
Free cash flow negative $22M in Q3; full-year guidance reduced to $150M-$250M due to divestiture costs.
“Free cash flow of ($22) million; revised free cash flow to a range of $150M to $250M.”
Adjusted operating income margin down 220 bps YoY due to tariffs, stand-up costs, and growth investments.
“Adjusted operating income margin declined 220 bps to 20.6%.”
Solventum Corporation — questions
- What did Solventum Corporation file recently?
- 15 SEC filings in the last 12 months. Latest: 8-K on 2026-08-05 — Solventum announces intent to separate Health Information Systems business, a portfolio optimization event that unlocks shareholder value and sharpens MedTech focus.
Every figure on this page comes from Solventum Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.